Fresenius Medical Care (NYSE:FMS) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Jun 1st, 2024

Research analysts at StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS – Get Free Report) in a note issued to investors on Saturday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial lifted their price target on Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Fresenius Medical Care has an average rating of “Hold” and an average target price of $32.25.

View Our Latest Stock Report on Fresenius Medical Care

Fresenius Medical Care Stock Performance

Shares of FMS opened at $21.28 on Friday. The company has a market capitalization of $12.48 billion, a PE ratio of 23.90, a price-to-earnings-growth ratio of 1.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.14. Fresenius Medical Care has a one year low of $16.37 and a one year high of $27.72. The company’s fifty day moving average price is $20.31 and its 200 day moving average price is $20.16.

Fresenius Medical Care (NYSE:FMS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.10. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.15 billion. As a group, analysts expect that Fresenius Medical Care will post 1.51 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care

Institutional investors have recently modified their holdings of the company. O Shaughnessy Asset Management LLC boosted its stake in Fresenius Medical Care by 259.5% during the third quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock worth $1,995,000 after buying an additional 66,864 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Fresenius Medical Care by 14,252.1% during the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after acquiring an additional 484,998 shares in the last quarter. VisionPoint Advisory Group LLC bought a new stake in Fresenius Medical Care in the fourth quarter valued at about $812,000. Partnership Wealth Management LLC acquired a new position in Fresenius Medical Care in the fourth quarter worth about $2,340,000. Finally, QRG Capital Management Inc. bought a new position in Fresenius Medical Care during the third quarter worth about $676,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

(Get Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.